# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Merck's two-drug HIV regimen doravirine/islatravir maintained viral suppression and matched Gilead's Biktarvy in Phase ...
n trial MK-8591A-052, adults living with virally suppressed HIV-1 infection who switched to DOR/ISL from BIC/FTC/TAF showed min...
Shah Capital urges Novavax to consider a sale after poor COVID-19 vaccine rollout, highlighting the potential value of at least...
Citigroup analyst Geoff Meacham reinstates Merck & Co (NYSE:MRK) with a Neutral and raises the price target from $84 to ...
UK ministers consider raising NHS drug spending by up to 25% amid pharma investment delays and pressure from US pricing policies.
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that it will present new findings from ...
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced new research from more than 100 abstrac...